GO:0004693 cyclin-dependent protein serine/threonine kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004693 describes the molecular function of cyclin-dependent kinases (CDKs), which transfer phosphate from ATP to serine or threonine residues on protein substrates.
• CDK activity is essential for cell-cycle progression, transcription, and other cellular processes, and is tightly regulated by cyclin binding and activating phosphorylation.
• The catalytic mechanism involves a conserved ATP-binding site and a phospho-acceptor residue on the substrate, with cyclins acting as regulatory subunits.
• Dysregulation of CDK activity is implicated in cancer, neurodegeneration, and viral infections, making CDKs important therapeutic targets.
• Key CDK genes include CDK1, CDK2, CDK4, CDK6, CDK7, and CDK20, each with distinct roles and research relevance.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of CDK function in health and disease.
Description
Cyclin-dependent protein serine/threonine kinase activity (GO:0004693) is a fundamental molecular function that governs cell division, transcription, and numerous other cellular processes. This activity is carried out by a family of enzymes known as cyclin-dependent kinases (CDKs), which require association with regulatory subunits called cyclins to become active. The defining feature of this GO term is the catalysis of phosphate transfer from ATP to serine or threonine residues on protein substrates, a reaction that is central to signal transduction and cell-cycle control. Researchers study this activity to understand how cells coordinate growth, proliferation, and differentiation, and how its dysregulation leads to diseases such as cancer and neurodegeneration. The importance of GO:0004693 extends to virology, as certain viruses encode cyclin-like proteins that hijack CDK activity to promote infection. Given its broad impact, precise experimental models are needed to dissect the roles of individual CDKs and their regulatory networks.
cyclin-dependent protein serine/threonine kinase activity At A Glance
| GO ID | GO:0004693 |
|---|---|
| GO term | cyclin-dependent protein serine/threonine kinase activity |
| Ontology | molecular_function |
| Synonym | CDK activity; cyclin-dependent kinase activity; cdc2 kinase activity; CDK, catalytic subunit activity; cyclin D-dependent kinase activity |
| Major function | Phosphorylation of serine/threonine residues on protein substrates, regulating cell cycle, transcription, and other processes |
| Catalytic mechanism | Transfer of the gamma-phosphate of ATP to a serine or threonine hydroxyl group on the substrate |
| Regulation | Activated by cyclin binding and by phosphorylation of a conserved threonine residue in the T-loop (e.g., Thr160 in CDK2) |
| Subcellular location | Predominantly nuclear and cytoplasmic, depending on the CDK-cyclin complex |
| Representative CDKs | CDK1, CDK2, CDK4, CDK6, CDK7, CDK20 |
What Is GO:0004693?
GO:0004693, cyclin-dependent protein serine/threonine kinase activity, is defined as the catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate, specifically when the catalytic activity depends on cyclin binding. In other words, it is the ability of an enzyme (a CDK) to add phosphate groups to serine or threonine residues on target proteins, a process that is switched on by cyclins and often fine-tuned by additional phosphorylation events.
Why Is cyclin-dependent protein serine/threonine kinase activity Important in Cell Biology?
Cyclin-dependent protein serine/threonine kinase activity is a cornerstone of cellular regulation, controlling the orderly progression of the cell cycle and the response to growth signals. Because CDKs are frequently deregulated in human diseases, especially cancer, they are major targets for therapeutic intervention. Understanding this activity at the molecular level is essential for developing specific inhibitors and for interpreting how mutations in CDK genes or their regulators contribute to disease.
• Drives cell-cycle progression by phosphorylating key substrates such as the retinoblastoma protein.
• Regulates transcription through phosphorylation of the RNA polymerase II C-terminal domain by CDK7 and CDK9.
• Is essential for neuronal development and function, with CDK5 and CDK20 playing specialized roles.
• Is exploited by viruses, which can encode cyclin homologs to manipulate host CDK activity.
• Dysregulation leads to uncontrolled proliferation in cancer, making CDKs drug targets.
• Mutations in CDK genes or their regulators cause developmental disorders and neurodegeneration.
• CDK activity is required for DNA replication and repair, linking it to genome stability.
• Provides a paradigm for understanding kinase regulation by subunit binding and phosphorylation.
• Enables high-throughput screening for inhibitors with potential clinical applications.
• Serves as a model system for studying enzyme kinetics and allosteric regulation.
What Happens During cyclin-dependent protein serine/threonine kinase activity?
Cyclin Binding and Activation
In simple terms: Cyclins act like keys that unlock the kinase, allowing it to work.
The first step in CDK activation is the binding of a cyclin regulatory subunit to the CDK catalytic subunit. This interaction induces conformational changes that align the catalytic residues and expose the substrate-binding site. Different cyclins pair with specific CDKs to control distinct cell-cycle phases or transcriptional programs.
Activating Phosphorylation
In simple terms: A phosphate tag on the kinase itself is needed for full activity.
Full activation of many CDKs requires phosphorylation of a conserved threonine residue in the T-loop by CDK-activating kinase (CAK), which is itself a CDK complex (CDK7-cyclin H-MAT1). For example, phosphorylation of Thr160 in CDK2 is critical for its activity.
Substrate Recognition and Phosphate Transfer
In simple terms: The active kinase finds its target protein and attaches a phosphate group.
Once activated, the CDK-cyclin complex recognizes specific serine or threonine residues on substrate proteins, often guided by consensus sequences and docking interactions. The gamma-phosphate of ATP is transferred to the hydroxyl group of the target residue, resulting in phosphorylation and a change in substrate function.
Inhibition and Turnover
In simple terms: The activity is switched off by inhibitors and by degradation of cyclins.
CDK activity is terminated by several mechanisms, including binding of CDK inhibitors (CKIs) such as p21 and p27, phosphorylation of inhibitory residues (e.g., Thr14 and Tyr15), and ubiquitin-mediated degradation of cyclins. These layers of control ensure that CDK activity is transient and precisely timed.
Key Genes Involved in GO:0004693 cyclin-dependent protein serine/threonine kinase activity
The following genes encode proteins that are directly involved in or regulate cyclin-dependent protein serine/threonine kinase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDK1 | Catalytic subunit of the M-phase promoting factor; phosphorylates mitotic substrates | Essential for mitosis; knockout is lethal in most organisms |
| CDK2 | Regulates G1/S transition and DNA replication; activated by cyclin E and A | Target in cancer; Thr160 phosphorylation studied |
| CDK4 | Phosphorylates RB in early G1; partners with cyclin D | Amplified in melanoma and other cancers; inhibitor target |
| CDK6 | Similar to CDK4; controls G1 progression | Involved in hematopoietic malignancies |
| CDK7 | CDK-activating kinase (CAK) subunit; also phosphorylates RNA Pol II | Essential for transcription and cell cycle; inhibitor development |
| CDK9 | Phosphorylates RNA Pol II CTD; regulates transcription elongation | Target in leukemia and other cancers |
| CDK5 | Neuronal kinase; activated by p35/p39, not cyclins | Implicated in neurodegeneration |
| CDK20 | Activates CDKL5 in cilia; regulates flagellar length | Ciliary signaling; rare disease |
| CCNA2 | Cyclin A2; activates CDK2 and CDK1 | Cell cycle regulation; cancer |
| CCNB1 | Cyclin B1; activates CDK1 | Mitosis; cancer |
| CCND1 | Cyclin D1; activates CDK4 and CDK6 | Oncogene; overexpressed in many cancers |
| CCNE1 | Cyclin E1; activates CDK2 | G1/S transition; cancer |
| CDKN1A | p21; inhibits CDK2 and CDK1 | Cell cycle arrest; tumor suppressor |
| CDKN2A | p16; inhibits CDK4 and CDK6 | Frequently mutated in cancer |
| CDC25A | Phosphatase that activates CDKs by removing inhibitory phosphates | Cell cycle checkpoint control |
| WEE1 | Kinase that adds inhibitory phosphates to CDKs | DNA damage response; drug target |
| MAT1 | Assembly factor for CDK7-cyclin H complex | CAK function |
How Is cyclin-dependent protein serine/threonine kinase activity Regulated?
Cyclin-dependent protein serine/threonine kinase activity is regulated at multiple levels. Cyclin binding is the primary switch, but additional control is exerted by activating phosphorylation of the T-loop by CAK and inhibitory phosphorylation by Wee1/Myt1 kinases. CDK inhibitors (CKIs) such as p21 and p27 bind and block activity, while ubiquitin-mediated proteolysis of cyclins ensures irreversible progression through the cell cycle. In addition, CDK7, as part of the general transcription factor TFIIH, is regulated by its association with MAT1 and cyclin H.
cyclin-dependent protein serine/threonine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CDK4 | Melanoma, breast cancer | Knockout in cancer cell lines; point mutation of catalytic residues |
| CDK7 | Cancer, transcription addiction | Knock-in of tagged CDK7 for proteomics; overexpression |
| CDK5 | Alzheimer's disease | Point mutation of phosphorylation sites; knockout in neurons |
| CDK20 | Ciliopathies, flagellar length defects | Knockout in Chlamydomonas; knock-in of patient mutations |
| CCND1 | Mantle cell lymphoma, breast cancer | Overexpression in cell lines; knockout in mouse models |
Cancer
Dysregulated CDK activity is a hallmark of cancer. Overexpression of cyclin D1 or amplification of CDK4/6 leads to hyperphosphorylation of RB and uncontrolled cell proliferation. CDK7 inhibitors are being developed as anticancer agents because CDK7 controls both cell-cycle progression and transcription. Targeting CDK activity with small molecules has shown clinical benefit in breast cancer and other malignancies.
Neurodegeneration
Aberrant activation of CDK5 by p25, a cleavage product of p35, contributes to neuronal death in Alzheimer's disease and other neurodegenerative conditions. CDK5 phosphorylates tau and other substrates, linking it to neurofibrillary tangles. CDK20 mutations are associated with ciliary dysfunction and rare disorders.
Viral Infections
Viruses can encode cyclin-like proteins that hijack host CDK activity to promote viral replication. For example, herpes simplex virus type 2 infection alters CDK activity, and some viruses encode functional cyclins. This highlights the role of CDKs in host-pathogen interactions.
From cyclin-dependent protein serine/threonine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CDK2 affect cell-cycle progression? | CDK2 knockout cell lines |
| How does Thr160 phosphorylation regulate CDK2 activity? | Point mutation (T160A) knock-in |
| What are the interaction partners of CDK7? | Tagged knock-in (e.g., GFP or HA) followed by immunoprecipitation |
| Does overexpression of cyclin D1 drive proliferation? | Cyclin D1 overexpression cell lines |
| Which genes are essential for CDK inhibitor resistance? | CRISPR library screening |
| How does CDK20 mutation affect ciliary length? | Knock-in of patient mutations in model organisms |
How to Study the cyclin-dependent protein serine/threonine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro kinase assay | Phosphate transfer to substrate | Measuring specific activity of CDK-cyclin complexes |
| Phosphoproteomics | Global phosphorylation changes | Identifying CDK substrates and pathways |
| CRISPR knockout screen | Gene essentiality and resistance | Finding modifiers of CDK inhibitor sensitivity |
| RNA-seq | Transcriptional changes | Assessing effects of CDK inhibition on gene expression |
| Proximity ligation assay | Protein-protein interactions | Detecting CDK-cyclin interactions in cells |
| Immunoblotting | Protein expression and phosphorylation | Validating CDK activation state |
| Flow cytometry | Cell-cycle distribution | Linking CDK activity to proliferation |
| Structural crystallography | 3D structure of CDK-cyclin complexes | Rational drug design |
Kinase Activity Assays
In vitro kinase assays using recombinant CDK-cyclin complexes and substrate peptides measure the catalytic activity directly. These assays can be coupled with ATP analogs or radioactive phosphate to quantify phosphate incorporation.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics identifies substrates and phosphorylation sites regulated by CDKs. This approach provides a global view of signaling networks downstream of CDK activity.
CRISPR Screens
Genome-wide CRISPR knockout or activation screens can identify genes that modulate CDK activity or sensitivity to CDK inhibitors. These screens are powerful for discovering synthetic lethal interactions.
Structural Biology
X-ray crystallography and cryo-EM reveal the conformational changes that accompany cyclin binding and T-loop phosphorylation, informing drug design.
How CRISPR Can Be Used to Study GO:0004693 cyclin-dependent protein serine/threonine kinase activity
Knockout
CRISPR knockout of CDK genes or their cyclin partners abolishes specific kinase activities, allowing researchers to study loss-of-function phenotypes. For example, CDK2 knockout cells show defects in DNA replication and G1/S transition. Knockout models are also used to validate drug targets.
Point Mutation
Introducing point mutations such as T160A in CDK2 or catalytic dead mutations (e.g., D145N) via CRISPR knock-in enables precise dissection of phosphorylation-dependent functions. These models are invaluable for distinguishing kinase-dependent from scaffold functions.
Knock-in
Knock-in of tags (e.g., GFP, HA, or BirA) at endogenous CDK loci allows for affinity purification, imaging, and proximity labeling. This approach preserves native regulation and stoichiometry, providing insights into CDK complex assembly and dynamics.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression of CDKs and cyclins can model gain-of-function states observed in cancer. Overexpression models are useful for testing inhibitors and studying oncogenic transformation.
How EDITGENE Supports cyclin-dependent protein serine/threonine kinase activity Research
Researchers studying cyclin-dependent protein serine/threonine kinase activity-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional studies.
Contact EDITGENE today to design your custom CRISPR model for cyclin-dependent protein serine/threonine kinase activity research.
Frequently Asked Questions About cyclin-dependent protein serine/threonine kinase activity
What is cyclin-dependent protein serine/threonine kinase activity?
It is the enzymatic activity of CDKs, which phosphorylate serine or threonine residues on target proteins in a cyclin-dependent manner, as defined by GO:0004693.
What genes are involved in cyclin-dependent protein serine/threonine kinase activity?
Key genes include CDK1, CDK2, CDK4, CDK6, CDK7, CDK9, CDK20, and their regulatory cyclins such as CCNA2, CCNB1, CCND1, and CCNE1.
How is CDK activity regulated?
CDK activity is regulated by cyclin binding, activating phosphorylation of the T-loop by CAK, inhibitory phosphorylation by Wee1, and binding of CDK inhibitors.
What diseases are associated with CDK dysregulation?
Cancer, neurodegeneration, and viral infections are linked to aberrant CDK activity.
What is the role of CDK7?
CDK7 is a CDK-activating kinase that phosphorylates other CDKs and also phosphorylates RNA polymerase II to regulate transcription.
How can CRISPR be used to study CDK function?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of CDK genes to study their roles in cells and disease.
What is the catalytic mechanism of CDKs?
CDKs transfer the gamma-phosphate of ATP to the hydroxyl group of serine or threonine on substrate proteins, facilitated by cyclin-induced conformational changes.
Which CDK is involved in ciliary length control?
CDK20 (also known as LF2) activates CDKL5 to control flagellar length.
What are CDK inhibitors?
Small molecules that block CDK activity, used in cancer therapy; examples include CDK4/6 inhibitors and CDK7 inhibitors in development.
How does phosphorylation of Thr160 affect CDK2?
Phosphorylation of Thr160 in the T-loop of CDK2 is required for full activity and substrate binding.
Conclusion
Cyclin-dependent protein serine/threonine kinase activity (GO:0004693) is a central molecular function that orchestrates cell division, transcription, and many other processes. Its precise regulation by cyclins, phosphorylation, and inhibitors ensures proper cellular function, while its dysregulation drives cancer, neurodegeneration, and viral pathogenesis. Continued research using advanced CRISPR models and biochemical assays will deepen our understanding of CDK biology and facilitate the development of targeted therapies.
References
- 1. Jung JU et al.. 1994. Virus-encoded cyclin.. Mol Cell Biol 14(11):7235-44 PMID: 7935438
- 2. Hou Y et al.. 2025. Activation of the ciliary kinase CDKL5 is mediated by the cyclin-dependent kinase CDK20/LF2 to control flagellar length.. PLoS Biol 23(12):e3003560 PMID: 41385589
- 3. Kovalová M et al.. 2023. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).. Expert Opin Ther Pat 33(2):67-87 PMID: 36975020
- 4. Clarke PR. 1995. Cyclin-dependent kinases. CAK-handed kinase activation.. Curr Biol 5(1):40-2 PMID: 7697347
- 5. Levine K et al.. 1995. Structuring cell-cycle biology.. Structure 3(11):1131-4 PMID: 8591023
- 6. Hossain A et al.. 1997. Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.. J Gen Virol 78 ( Pt 12):3341-8 PMID: 9400986
- 7. Brown NR et al.. 1999. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity.. J Biol Chem 274(13):8746-56 PMID: 10085115
- 8. Shuttleworth J. 1995. The regulation and functions of cdk7.. Prog Cell Cycle Res 1:229-40 PMID: 9552366
